251 related articles for article (PubMed ID: 30430605)
1. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Shiffman M; Freilich B; Vuppalanchi R; Watt K; Chan JL; Spada A; Hagerty DT; Schiff E
Aliment Pharmacol Ther; 2019 Jan; 49(1):64-73. PubMed ID: 30430605
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
3. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
[TBL] [Abstract][Full Text] [Related]
4. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
5. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
6. Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
Garcia-Tsao G; Fuchs M; Shiffman M; Borg BB; Pyrsopoulos N; Shetty K; Gallegos-Orozco JF; Reddy KR; Feyssa E; Chan JL; Yamashita M; Robinson JM; Spada AP; Hagerty DT; Bosch J
Hepatology; 2019 Feb; 69(2):717-728. PubMed ID: 30063802
[TBL] [Abstract][Full Text] [Related]
7. A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.
Mehta G; Rousell S; Burgess G; Morris M; Wright G; McPherson S; Frenette C; Cave M; Hagerty DT; Spada A; Jalan R
J Clin Exp Hepatol; 2018 Sep; 8(3):224-234. PubMed ID: 30302038
[TBL] [Abstract][Full Text] [Related]
8. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis.
Weinberg EM; Curry MP; Frenette CT; Regenstein FG; Schiff ER; Goodman ZD; Robinson JM; Chan JL; Imperial JC; Reddy KR
Liver Transpl; 2021 Apr; 27(4):568-579. PubMed ID: 33164276
[TBL] [Abstract][Full Text] [Related]
10. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
Schwimmer JB; Lavine JE; Wilson LA; Neuschwander-Tetri BA; Xanthakos SA; Kohli R; Barlow SE; Vos MB; Karpen SJ; Molleston JP; Whitington PF; Rosenthal P; Jain AK; Murray KF; Brunt EM; Kleiner DE; Van Natta ML; Clark JM; Tonascia J; Doo E;
Gastroenterology; 2016 Dec; 151(6):1141-1154.e9. PubMed ID: 27569726
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
[TBL] [Abstract][Full Text] [Related]
12. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
13. Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD).
Chong CYL; Orr D; Plank LD; Vatanen T; O'Sullivan JM; Murphy R
Nutrients; 2020 Mar; 12(4):. PubMed ID: 32230987
[No Abstract] [Full Text] [Related]
14. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S; Schattenberg JM; Demir M; Wiegand J; Geier A; Teuber G; Hofmann WP; Kremer AE; Spreda F; Kluwe J; Petersen J; Boettler T; Rainer F; Halilbasic E; Greinwald R; Pröls M; Manns MP; Fickert P; Trauner M;
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):781-793. PubMed ID: 31345778
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of fermented turmeric powder in subjects with elevated alanine transaminase levels: a randomised controlled study.
Kim SW; Ha KC; Choi EK; Jung SY; Kim MG; Kwon DY; Yang HJ; Kim MJ; Kang HJ; Back HI; Kim SY; Park SH; Baek HY; Kim YJ; Lee JY; Chae SW
BMC Complement Altern Med; 2013 Mar; 13():58. PubMed ID: 23497020
[TBL] [Abstract][Full Text] [Related]
16. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C.
Shiffman ML; Pockros P; McHutchison JG; Schiff ER; Morris M; Burgess G
Aliment Pharmacol Ther; 2010 May; 31(9):969-78. PubMed ID: 20163376
[TBL] [Abstract][Full Text] [Related]
18. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T; Imajo K; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Kobayashi N; Saito S; Nakajima A
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):996-1007. PubMed ID: 32805205
[TBL] [Abstract][Full Text] [Related]
19. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study.
Geier A; Eichinger M; Stirnimann G; Semela D; Tay F; Seifert B; Tschopp O; Bantel H; Jahn D; Marques Maggio E; Saleh L; Bischoff-Ferrari HA; Müllhaupt B; Dufour JF
Scand J Gastroenterol; 2018 Sep; 53(9):1114-1120. PubMed ID: 30270688
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease.
Chalasani N; Vuppalanchi R; Rinella M; Middleton MS; Siddiqui MS; Barritt AS; Kolterman O; Flores O; Alonso C; Iruarrizaga-Lejarreta M; Gil-Redondo R; Sirlin CB; Zemel MB
Aliment Pharmacol Ther; 2018 Jun; 47(12):1639-1651. PubMed ID: 29696666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
